Navigation Links
New Positron Emission Tomography (PET) Biomarker NVB-64 Visualizes Malignant Breast Tumors
Date:10/29/2009

kly became the preferred method of breast cancer detection. Not until 2004 was the first non-surgical procedure looking towards breast cancer detection using Positron Emission Tomography (PET) with 18fluorodeoxyglucose (FDG) approved for use in patients. FDG-PET has two significant drawbacks: 1) FDG-PET leaves a frustrating 30% of tumors undetected; and 2) FDG cannot reliably distinguish between benign and malignant tumors.

The significant advance of NVB-64 is the recognition of genetic changes at the cellular level, as a genomic biomarker, rather than the overly generalized metabolic markers found with FDG.

Nearly as important as the human implications are the enormous financial ramifications. Lead investigator Mathew Thakur Ph.D. Professor of Radiology and Director of the Laboratories of Radiopharmaceutical Research and Molecular Imaging at Thomas Jefferson University Hospital says, "The use of NVB64-PET scan in the future may minimize the need for unnecessary biopsy of benign tumors." Currently, nearly 6 million such biopsies are performed annually in the United States, at an estimated annual cost of $30 billion. Approximately 80% or 4.8 million biopsies, demonstrate benign pathology.

The biomarkers NuView has in development can, with alteration of the radionuclide attached to the compound, change them from a diagnostic to a targeted therapy, or a pairing of a target specific diagnostic and therapy. NuView Medical Director Peter S. Conti, MD, PhD adds, "Development of targeted diagnostics that can be modified to also carry therapeutic isotopes can lead to unique agents that can broaden the range of therapies available for cancer patients."

Anticipated Benefits of NVB-64:

  • Same day, immediate confirmation of the patient having either benign or malignant breast tumor(s).
  • Choice of care in selecting a screening method to determine the malignant or benign status of a mass found on a mammogram.'/>"/>

SOURCE NuView Life Sciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
2. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
3. FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET)
4. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
5. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
6. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
7. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
8. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
9. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
10. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
11. Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... SAN JOSE, California , 2 marzo 2015 ... che ha aperto la strada alla fusione con ... dell,articolazione sacroiliaca (SI) con iFuse Implant System ® ... iFuse sono stati eseguiti nel mondo intero utilizzando ... tecnica chirurgica iFuse viene sempre più adottata guadagnando ...
(Date:3/2/2015)... March 2, 2015 Shire plc (LSE: ... company has submitted a New Drug Application (NDA) with the ... lifitegrast for the treatment of signs and symptoms of dry ... be the first treatment indicated to address both the signs ... which affects millions of people," said Philip J. Vickers ...
(Date:3/2/2015)... N.J. and BETHESDA, Md. ... development-stage immunotherapy company focused on treating and preventing autoimmune ... 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen (NASDAQ: ... exclusive license agreement, Celimmune has the rights to develop, ... excluding Japan . Concurrently, Amgen has ...
Breaking Medicine Technology:SI-BONE, Inc. rivela l'obiettivo di 15.000 interventi con iFuse 2SI-BONE, Inc. rivela l'obiettivo di 15.000 interventi con iFuse 3SI-BONE, Inc. rivela l'obiettivo di 15.000 interventi con iFuse 4Shire Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults 2Shire Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults 3Shire Submits Application to the U.S. FDA for Approval of Lifitegrast for Treatment of Dry Eye Disease in Adults 4Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 2Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 3
... LYON, France, May 11, 2012 Mylan Inc. (Nasdaq: ... launched Atorvastatin Calcium Tablets, 10 mg, 20 mg, 40 ... the Netherlands and Ireland. Mylan has received marketing authorization ... its product immediately. Atorvastatin Calcium is the generic version ...
... /PRNewswire-iReach/ -- Electrochemical Oxygen Concepts (EO2™ ... chronic wound treatment device, announced it has been ... Federal Supply Schedule (FSS) contract, administered by The ... ® , a noninvasive, electrochemical low-dose tissue oxygenation ...
Cached Medicine Technology:Mylan Launches Generic Lipitor® in Five European Countries 2New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program 2New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program 3
(Date:3/2/2015)... The Workgroup for Electronic Data Interchange (WEDI), the ... IT to create efficiencies in healthcare information exchange, released ... The white paper by WEDI’s ICD-10 Testing Subworkgroup provides ... by focusing on primary considerations and steps for external ... 1, 2015 implementation date. Download the white paper ...
(Date:3/2/2015)... The minimally invasive surgical instruments ... of 6.1% to reach $14,133.0 million by 2019 ... such as advantages of minimally invasive surgeries over ... minimally invasive surgeries and increasing number of surgical ... global minimally invasive surgical instruments market. , For ...
(Date:3/2/2015)... 02, 2015 Dinner preparation and ... to the success of DinnerDork , a ... and delicious for thousands of busy customers. The ... by expanding to offer a total of 6 ... seasonally appropriate classic recipes and comfort foods; Paleo ...
(Date:3/2/2015)... Regulatory Compliance Associates® Inc. (RCA), ... and technical consulting, announces Mr. Seyed Khorashahi has ... , Before joining RCA, Mr. Khorashahi had over ... all aspects of developing safety-critical medical devices. ... Regulatory Compliance Associates Inc., Baxter Healthcare, and Beckman ...
(Date:3/2/2015)... March 02, 2015 What are the ... physicians request references? When are interviews scheduled, how can ... opportunities?, Both training and practicing physicians who are looking ... questions and more at the PracticeLink Physician Career Advancement ... drop-in Job Fair is from 5:30 to 8:30 p.m. ...
Breaking Medicine News(10 mins):Health News:WEDI Releases New White Paper on ICD-10 Testing for Small Providers 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 2Health News:DinnerDork Announces New Meal Planning Support for the Home Cook 3Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:PracticeLink to Host a Career Advancement Workshop and Job Fair in Houston 2
... Study finds twice the incidence of ,food insecurity, , , TUESDAY, ... smokers are more likely to be underfed and undernourished, a ... members of smoking households, but children feel the impact the ... at New York University School of Medicine. , "We know ...
... 4 AlphaDetail, Inc. is growing.,As a leader ... to the Global Life Sciences Industry, the company ... senior staff members to its Professional,Services Group., ... based in,Alphadetail,s San Mateo, California headquarters office. Gloria ...
... Misonix, Inc.,(Nasdaq: MSON ), today announced that ... supplier of after market products, services,and test equipment ... study in Sweden at the country,s annual clinical ... was presented by the School,for Technology and Health, ...
... organs and other internal structures of the human body. ... that can predict the sound transmission of improved designs ... processing large quantities of data and can be run ... University Medical Centre and Oldelft Ultrasound are now using ...
... 2008) In the first-ever study of its kind, a ... Research Institute at Harbor-UCLA Medical Center (LA BioMed) report ... Hispanics took longer to respond to medication for depression ... English-speaking Hispanics. , Using data from the nation,s largest ...
... by nearly 100%, operating loss reduced by 44%, ... ), a leading provider of quantitative imaging for clinical,trials, ... 2008 were,over $1.8 million, a 33% increase over prior ... 30, 2008 were approximately $5.2,million compared to nearly $4.2 ...
Cached Medicine News:Health News:Smokers' Homes More Likely to House Hungry Kids 2Health News:Smokers' Homes More Likely to House Hungry Kids 3Health News:AlphaDetail, Inc. Continues Bi-coastal Expansion 2Health News:Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study 2Health News:Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study 3Health News:Misonix Subsidiary, Sonora Medical Systems, Announces a Major Ultrasound Probe Study 4Health News:Response rates to antidepressants differ among English- and Spanish-speaking Hispanics 2Health News:VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 2Health News:VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 3Health News:VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 4Health News:VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 5Health News:VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit 6
... drapes from Cardinal Health will change the ... in your facility. , ,Shrinking budgets and ... controlled at every turn without sacrificing the ... Each decision must be evaluated from the ...
... Drape features less aggressive adhesive strip ... strip for easy removal, aggressive incise ... poly film, and product number identification. ... box of 5 or non-sterile in ...
... and near patient testing is growing 13 ... posed unique problems for hospitals and clinical ... to decentralized areas focused on patient care ... is the reality of controlling staffing costs ...
... includes genomic DNA Arrays, an ... By utilizing Vysis' patented comparative ... multi-target assessment, the GenoSensor is ... targets in a single test ...
Medicine Products: